back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-16 15:51 Tx date 2026-03-13 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-77,867.25
-1,410 vol $55.23 each |
7,069 | |
| Filed 2026-03-16 15:50 Tx date 2026-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+3,750 vol |
8,479 | |
| Filed 2026-03-16 15:49 Tx date 2026-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-3,750 vol |
31,250 | |
| Filed 2026-03-13 15:33 Tx date 2026-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$-166,559.268
-2,771 vol $60.11 each |
4,729 | |
| Filed 2026-03-13 15:31 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
57 - Exercise of rights
|
-7,500 vol |
0 | |
| Filed 2026-03-13 15:29 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+7,500 vol |
7,500 | |
| Filed 2026-03-13 15:27 Tx date 2026-03-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
+7,500 vol |
7,500 | |
| Filed 2026-03-13 15:25 Tx date 2021-08-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-01-12 18:19 Tx date 2026-01-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
50 - Grant of options
|
+20,000 vol |
35,000 | |
| Filed 2026-01-12 18:18 Tx date 2026-01-09 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
575,000 | |
| Filed 2025-06-10 13:59 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
50 - Grant of options
|
+15,000 vol |
15,000 | |
| Filed 2025-06-10 13:58 Tx date 2021-08-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-03-14 14:50 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+15,000 vol |
||
| Filed 2025-03-14 14:50 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+15,000 vol |
490,000 | |
| Filed 2025-03-14 14:49 Tx date 2025-03-12 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+80,000 vol |
475,000 | |
| Filed 2023-03-24 19:31 Tx date 2023-03-24 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-24,507
-700 vol $35.01 each |
0 | |
| Filed 2023-03-14 17:06 Tx date 2023-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+120,000 vol |
395,000 | |
| Filed 2022-03-14 17:12 Tx date 2022-03-10 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+125,000 vol |
275,000 | |
| Filed 2022-01-21 17:09 Tx date 2022-01-21 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$20,167
+700 vol $28.81 each |
700 | |
| Filed 2022-01-21 17:07 Tx date 2021-08-23 |
$XENE
Xenon Pharmaceuticals Inc. |
Kenney, Christopher John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|